{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-25-007893","form_type":"8-K","ticker":"NDRA","cik":"0001681682","company_name":"ENDRA Life Sciences Inc.","filed_at":"2025-07-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.628200+00:00","generated_at":"2026-05-18T08:54:04.455033+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ENDRA Life Sciences reports Q2 preliminary: no revenue, operating loss $1.3M","bullets":["No revenue for quarter ended June 30, 2025; same as Q2 2024 with zero revenue.","Expected operating loss of ~$1.3M, improved from ~$2.2M loss in Q2 2024.","As of June 30, 2025: cash and equivalents $1.8M; total assets $2.6M; working capital $1.2M.","Firm filed S-1 registration statement to offer shares and warrants in a public offering."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-25-007893","json":"https://secwatch.observer/filing/0001654954-25-007893.json","markdown":"https://secwatch.observer/filing/0001654954-25-007893.md","text":"https://secwatch.observer/filing/0001654954-25-007893.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681682/000165495425007893/0001654954-25-007893-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681682/000165495425007893/endra_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T08:54:04.455033+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}